<DOC>
	<DOCNO>NCT00112073</DOCNO>
	<brief_summary>The purpose study assess safety tolerability multiple dose AAB-001 passive immunization patient mild moderate Alzheimer 's disease ( AD ) .</brief_summary>
	<brief_title>AAB-001 Patients With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>The humanized monoclonal antibody , AAB-001 , bind clear beta amyloid peptide , design provide antibody beta amyloid directly patient , rather require patient mount his/her individual response . It believe approach may eliminate need patient mount immune response beta amyloid . Animal study show approach equally effective clearing beta amyloid brain traditional active immunization method . This multicenter , double-blind , placebo control , randomize , outpatient , multiple ascend dose study male female patient age 50 85 year mild moderate AD . Approximately 30 study site involve . Patients randomize receive either AAB-001 placebo . Each patient 's participation last approximately 2 year .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis probable AD Age 50 85 year Rosen Modified Hachinski Ischemic score less equal 4 Magnetic resonance imaging ( MRI ) scan consistent diagnosis AD Fluency English Stable dose medication Significant neurological disease AD Major psychiatric disorder Significant systemic illness History stroke seizure Weight great 120 kg ( 264 lb . ) History autoimmune disease Smoking 20 cigarette per day Anticonvulsants , antiParkinson 's , anticoagulant , narcotic medication Prior treatment experimental immunotherapeutics vaccine AD Presence pacemaker foreign metal object eye , skin , body</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>beta amyloid</keyword>
</DOC>